Abstract | PURPOSE: METHODS: K562 cells were pre-treated with 10 nM siRNA for 48 h and then treated with varying amount of CPX-351 for 24, 48 and 72 h. Cells were then collected and analyzed at 480/590 nm on a CytoFLEX Multicolour flow instrument to determine cellular uptake of daunorubicin. Experimental data were analyzed using two-way ANOVA with Bonferroni multiple comparisons. Significance was set at p < .05. RESULTS: K562 cells pre-treated with SR-BI siRNA for 48 h had a reduced SRB1 cell surface concentration (74-85%). Addition of CPX-351 at 10-50 nM followed by measurement of cellular daunorubicin at 48, 48 or 72 h showed a significantly lower percentage of daunorubicin positive population compared with control K562 cells (p < .05). There was significantly less daunorubicin taken up in the SR-BI knock-down cells across all drug concentrations and at all three time points, although there were no concentration-related trends. CONCLUSIONS: These preliminary studies suggest that SR-BI may be one potential mechanism by which CPX-351 is taken up into K562 cells.
|
Authors | Yunyun Di, Ellen K Wasan, Jacqueline Cawthray, Kishor M Wasan |
Journal | Drug development and industrial pharmacy
(Drug Dev Ind Pharm)
Vol. 45
Issue 1
Pg. 21-26
(Jan 2019)
ISSN: 1520-5762 [Electronic] England |
PMID | 30113235
(Publication Type: Journal Article)
|
Chemical References |
- CPX-351
- RNA, Small Interfering
- Receptors, Scavenger
- SCARB1 protein, human
- Scavenger Receptors, Class B
- Cytarabine
- Daunorubicin
|
Topics |
- Cell Membrane
(drug effects, metabolism)
- Cytarabine
(metabolism, pharmacology)
- Daunorubicin
(metabolism, pharmacology)
- Humans
- K562 Cells
- RNA, Small Interfering
(pharmacology)
- Receptors, Scavenger
(metabolism)
- Scavenger Receptors, Class B
(metabolism)
|